Company news
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news
Syndax Pharmaceuticals, Inc. news releases on 6ix. Latest, Nov 4, 2021: Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical…
Press releases — page 4
Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting
November 3, 2021
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
September 26, 2021
Syndax Appoints Martin H. Huber, M.D., to its Board of Directors
September 14, 2021
Syndax Announces Participation at Three Upcoming Investor Conferences
September 1, 2021
Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update
August 8, 2021
Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
August 1, 2021
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
June 27, 2021
Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
June 2, 2021
Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 12, 2021
Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update
May 10, 2021
Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
May 3, 2021
Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias
April 19, 2021
Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias
April 14, 2021
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis
April 7, 2021
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease
March 30, 2021
Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update
March 7, 2021
Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021
February 28, 2021
Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index
December 17, 2020
Syndax Announces Pricing of Public Offering of Common Stock
December 8, 2020
Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD
December 5, 2020
Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts
November 29, 2020
Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference
November 10, 2020
Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update
November 1, 2020
Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020
October 25, 2020
Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
August 5, 2020
Syndax Announces Participation in BTIG Virtual Biotechnology Conference
August 2, 2020
Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
July 29, 2020
Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer
July 6, 2020
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
May 6, 2020
Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020
April 29, 2020
Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias
April 26, 2020
Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting
April 13, 2020
Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update
March 2, 2020
Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million
January 30, 2020
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
January 9, 2020
Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease
December 9, 2019
Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias
December 8, 2019
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
November 6, 2019
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
November 5, 2019
Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019
October 30, 2019
Syndax Announces Participation at Four Upcoming Investor Conferences
August 27, 2019
Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update
August 6, 2019
Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019
July 30, 2019
Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias
July 9, 2019